Skip to main content

Advertisement

SpringerLink
Log in

Chronic intestinal pseudo-obstruction

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

For many patients, nutritional support and relief of symptoms remain the primary management goal of pseudo-obstruction. Specific pharmacological agents for this disorder are, in general, lacking. Given that the efficacy of many of the individual available agents is far from excellent, several centers have turned to combination therapy. Though there is at present no evidence from controlled studies to support this strategy, it is, at the very least, theoretically attractive as these agents act through a number of separate mechanisms. The combination of a prokinetic and an emetic may prove especially useful. As the pseudo-obstruction syndromes are, individually, rare, and experience with any given prokinetic agent in these disorders limited, it is difficult to develop strict guidelines for their use in this context. It stands to reason that a response to a prokinetic agent would seem unlikely in a patient with an advanced myopathic process; anecdotal evidence suggests, however, that some patients with severe scleroderma may derive some symptomatic improvement. Where oral therapy is tolerated, cisapride would appear the best choice among available agents. When this fails, subcutaneous octreotide may be added or substituted. In the acute situation, intravenous erythromycin may alleviate gastroparesis, but probably exerts little beneficial effect beyond the pylorus; parenteral metoclopramide may be tried, but, here again, convincing evidence of efficacy is lacking. The roles of endoscopy and surgery are largely confined to facilitating nutrition and providing decompression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Camilleri M: Disorders of gastrointestinal motility in neurologic diseases. Mayo Clin Proc 1990, 65:825–846.

    PubMed  CAS  Google Scholar 

  2. Krishnamurthy S, Schuffler MD: Pathology of neuromuscular disorders of the small intestine and colon. Gastroenterology 1987, 93:610–639.

    PubMed  CAS  Google Scholar 

  3. Colemont LJ, Camilleri M: Chronic intestinal pseudoobstruction: diagnosis and treatment. Mayo Clin Proc 1989, 64:60–70.

    PubMed  CAS  Google Scholar 

  4. Kobayashi T, Kobayashi M, Naka M, et al.: Response to octreotide of intestinal pseudoobstruction and pneumatosis cystoides intestinalis associated with progressive systemic sclerosis. Intern Med 1993, 32:607–609.

    PubMed  CAS  Google Scholar 

  5. Tak PP, Van Duinen CM, Bun P, et al.: Pneumatosis cystoides intestinalis in intestinal pseudoobstruction. Resolution after therapy with metronidazole. Dig Dis Sci 1992, 37:949–954.

    Article  PubMed  CAS  Google Scholar 

  6. Luks FI, Chung MA, Brandt ML, et al.: Pneumatosis and pneumoperitoneum in chronic idiopathic intestinal pseudoobstruction. J Pediatr Surg 1991, 26:1384–1386.

    Article  PubMed  CAS  Google Scholar 

  7. Sjogren RW. Gastrointestinal motility disorders in scleroderma Arthritis Rheum 1994, 37:1265–1782. A comprehensive review of the gastrointstinal features of one of the most common causes of pseudo obstruction.

    Article  PubMed  CAS  Google Scholar 

  8. Nojima Y, Mimura T, Hamasaki K, et al.: Chronic intestinal pseudoobstruction associated with autoantibodies against proliferating cell nuclear antigen. Arthritis Rheum 1996, 39:877–879.

    Article  PubMed  CAS  Google Scholar 

  9. Cacoub P, Benhamou Y Barbet P, et al.: Systemic lupus erythrematosus and chronic intestinal pseudoobstruction. J Rheumatol 1993, 20:377–381.

    PubMed  CAS  Google Scholar 

  10. Ljubich P, Parkman HP, Fisher RS, et al.: Diffuse gastrointestinal dysmotility in a patient with rheumatoid arthritis. Am J Gastroenterol 1993, 88:1443.

    PubMed  CAS  Google Scholar 

  11. Bensen ES, Jaffe KM, Tarr PI: Acute gastric dilatation in Duchenne muscular dystrophy: a case report and review of the literature. Arch Phys Med Rehabil 1996, 77:512–514.

    Article  PubMed  CAS  Google Scholar 

  12. Fuger, K. Barnert J, Hopfner W, Wienbeck M: Intestinal pseudoobstrction as a feature of myotonic muscular dystrophy. Z Gastroenterol 1995, 33[9]:534–538.

    Google Scholar 

  13. Bassotti G, Pagliacci MC, Nicoletti I, et al.: Intestinal pseudoobstruction secondary to hypothyroidism. Importance of small bowel manometry. J Clin Gastroenterol 1992, 14:56–58.

    Article  PubMed  CAS  Google Scholar 

  14. Hiramatsu K, Kaneko S, Shirota Y, et al.: Gastrointestinal amyloidosis secondary to hypersensitivity vasculitis presenting with intestinal pseudoobstruction. Dig Dis Sci 1998, 43:1824–1830.

    Article  PubMed  CAS  Google Scholar 

  15. Gerl A, Storck M, Schalhorn A, et al.: Paraneoplastic chronic intestinal pseudoobstruction as a rare complication of bronchial carcinoid. Gut 1992, 33:1000–1003.

    PubMed  CAS  Google Scholar 

  16. Lennon VA, Sas DF, Busk MF, et al.: Enteric neuronal autoantibodies in pseudoobstruction with small-cell lung carcinoma. Gastroenterology 1991, 100:137–142.

    PubMed  CAS  Google Scholar 

  17. Ikoma A, Nakada K, Suzuki T, et al.: Gastrointestinal motility in the immediate postoperative period after intestinal transplantation, with special reference to acute rejection. Transplant Proc 1994, 26:1657–1658.

    PubMed  CAS  Google Scholar 

  18. Uc A, Vasiliauskas E, Piccoli DA, et al.: Chronic intestinal pseudoobstruction associated with fetal alcohol syndrome. Dig Dis Sci 1997, 42:1163–1167.

    Article  PubMed  CAS  Google Scholar 

  19. Husebye E, Hauer-Jensen M, Kjorstad K, Skar V: Severe late radiation enteropathy is characterized by impaired motility of proximal small intestine. Dig Dis Sci 1994, 39:2341–2349.

    Article  PubMed  CAS  Google Scholar 

  20. Camilleri M, Carbone LD, Schuffler MD: Familial enteric neuropathy with pseudoobstruction. Dig Dis Sci 1991, 36:1168–1171.

    Article  PubMed  CAS  Google Scholar 

  21. Ozok G, Erdener A, Herek O, et al.: Microcolon-intestinal hypoperistalsis without megacystis: uncommon form of neonatal intestinal pseudoobstruction. Eur J Pediatr Surg 1995, 5:124–127.

    PubMed  CAS  Google Scholar 

  22. Li V, Hostein J, Romero NB, et al.: Chronic intestinal pseudoobstruction with myopathy and opthalmoplegia. A muscular biochemical study of a mitochondrial disorder. Dig Dis Sci 1992, 37:456–463.

    Article  PubMed  CAS  Google Scholar 

  23. Thompson DG: The clinical application of exhaled breath hydrogen testing for the study of gastrointestinal motility. In: In Read NW, ed. Gastrointestinal motility, which test? Petersfield, England: Wrightson Biomedical Publishing, 1989:163–167.

    Google Scholar 

  24. Camilleri M, Zinsmeister AR, Greydanus MP, et al.: Towards a less costly but accurate test of gastric emptying and small bowel transit. Dig Dis Sci 1991, 36:609–615.

    Article  PubMed  CAS  Google Scholar 

  25. Charles F, Camilleri M, Phillips SF, et al.: Scintigraphy of the whole gut: clinical evaluation of transit disorders. Mayo Clinic Proc 1995, 70:113–118.

    CAS  Google Scholar 

  26. Quigley EMM: Intestinal manometry-technical advances; clinical limitations. Dig Dis Sci 1992, 37:10–13.

    Article  PubMed  CAS  Google Scholar 

  27. Quigley EMM, Deprez P, Hellstrom P, et al.: Ambulatory intestinal manometry: a consensus report on its clinical role. Dig Dis Sci 1997, 42:2395–2400.

    Article  PubMed  CAS  Google Scholar 

  28. Boige N, Faure C, Cargill G, et al.: Manometrical evaluation in visceral neuropathies in children. J Pediatr Gastroenterol Nutr 1994, 19:71–77.

    Article  PubMed  CAS  Google Scholar 

  29. Cucchiara S, Annese V, Minella R, et al.: Antroduodenojejunal manometry in the diagnosis of chronic idiopathic intestinal pseudoobstruction in children. J Pediatr Gastroenterol Nutr 1994, 18:297–305.

    Article  Google Scholar 

  30. Quigley EMM: Enteric neuropathology - recent advances and implications for clinical practice. The Gastroenterologist 1997, 5:233–241. A detailed review of the pathologic basis of gastrointestinal dysmotility. Emphasizes the existence of evidence for an organic basis for many clinical dysmotility syndromes. Provides an update on current views on the pathophysiology of motor disorders.

    PubMed  CAS  Google Scholar 

  31. Yamataka A, Ohshiro K, Kobayashi H, et al.: Abnormal distribution of intestinal pacemaker [C-KIT-positive] cells in an infant with chronic idiopathic intestinal pseudoobstruction. J Pediatr Surg 1998, 33:859–862.

    Article  PubMed  CAS  Google Scholar 

  32. Perez-Atayde AR, Fox V, Teitelbaum JE, et al.: Mitochondrial neurogastrointestinal encephalomyopathy: diagnosis by rectal biopsy. Am J Surg Pathol 1998, 22:1141–1147.

    Article  PubMed  CAS  Google Scholar 

  33. Auricchio A, Brancolini V, Casdari G, et al.: The locus for a novel syndromic form of neuronal intestinal pseudoobstruction maps to Xq28. Am J Hum Genet 1996, 58:743–748.

    PubMed  CAS  Google Scholar 

  34. Chakravarti A, Blanton S, Kendall BJ, McCallum RW: Cosegregation of familial intestinal pseudoobstruction and presence of digital arches in a large multigenerational pedigree. Dig Dis Sci 1996, 41:1429–1433.

    Article  PubMed  CAS  Google Scholar 

  35. Pulliam TJ, Schuster MM: Congenital markers for chronic intestinal pseudoobstruction. Am J Gastroenterol 1995, 90:922–926.

    PubMed  CAS  Google Scholar 

  36. Debinski HS, Ahmed S, Milla PJ, Kamm MA: Electrogastrography in chronic intestinal pseudoobstruction. Dig Dis Sci 1996, 41:1292–1297.

    Article  PubMed  CAS  Google Scholar 

  37. Devane SP, Ravelli AM, Bisset WM, et al.: Gastric antral dysrhythmias in children with chronic idiopathic intestinal pseudoobstruction. Gut 1992, 33:1477–1481.

    PubMed  CAS  Google Scholar 

  38. Frank JW, Sarr MG, Camilleri M: Use of gastroduodenal manometry to differentiate mechanical and functional intestinal obstruction: an analysis of clinical outcome. Am J Gastro 1994, 89:334–344.

    Google Scholar 

  39. Camilleri M. Appraisal of medium- and long-term treatment of gastroparesis and chronic intestinal dysmotility. Am J Gastroenterol 1994, 89:1769–1774. A practical overview of the current status of dysmotility therapeutics.

    PubMed  CAS  Google Scholar 

  40. Perisic VN, Scepanovic D, Radlovic N: Intestinal pseudoobstruction and phytobezoar. J Pediatr Gastroenterol Nutr 1995, 20:238–239.

    Article  PubMed  CAS  Google Scholar 

  41. Baskin WN: Advances in enteral nutrition techniques. Am J Gastroenterol 1992, 11:1547–1553.

    Google Scholar 

  42. Burtch GD, Shatney CH: Feeding jejunostomy [versus gastrostomy] passes the test of time. Am Surg 1987, 53:54–57.

    PubMed  CAS  Google Scholar 

  43. Quigley EMM: The clinical pharmacology of motility disorders: the perils [and pearls] of prokinesia. Gastroenterology 1994, 106:1112–1114.

    PubMed  CAS  Google Scholar 

  44. Scarpignato C: Pharmacological stimulation of gastrointestinal motility: where we are and where are we going? Dig Dis 1997, 15:112–136. A comprehensive review of the current status of motility pharmacology.

    PubMed  Google Scholar 

  45. Verne GN, Eaker EY, Hardy E, Sninsky CA: Effect of octrotide and erthythromycin on idiopathic and scleroderma-associated intestinal pseudoobstruction. Dig Dis Sci. 1995, 40:1892–1901.

    Article  PubMed  CAS  Google Scholar 

  46. Malagelada J-R, Rees WDW, Mazzotta LJ, Go VLW: Gastric motor abnormalities in diabetic and post vagotomy gastroparesis: effect of metoclopramide and bethanechol. Gastroenterology 1980, 78:286–293.

    PubMed  CAS  Google Scholar 

  47. Brogden RM, Carmine AA, Heel RC, et al.: Domperidone. Drugs 1982, 24:360–400.

    PubMed  CAS  Google Scholar 

  48. Champion MC, Hartnett M, Yen M: Domperidone, a new dopamine antagonist. Can Med Assoc Journal 1986, 135:457–461.

    CAS  Google Scholar 

  49. Silvers D, Kipnes M, Broadstone V, et al.: DOM-USA-5 Study Group. Domperidone in the management of symptoms of diabetic gastroparesis: efficacy, safety and quality-of-life outcomes in a multicenter-controlled trial. Clin Therap 1998, 20:438–453.

    Article  CAS  Google Scholar 

  50. Farup C, Leidy MK, Murray M, et al.: The effect of domperidone on the health related quality of life of patients with diabetic gastropathy. Diabetes Care 1998, 21:1699–1706.

    Article  PubMed  CAS  Google Scholar 

  51. Hawkey CJ: The place of cisapride in therapeutics: an interim verdict. Aliment Pharmacol & Therap 1991, 5:351–356.

    Article  CAS  Google Scholar 

  52. Abell TL, Camilleri M, DiMagno EP, et al.: Long-term efficacy of oral cisapride in symptomatic upper gut dysmotility. Dig Dis Sci 1991, 36:621–626.

    Article  Google Scholar 

  53. Wehrmann T, Lembcke B, Caspary WF: Influence of cisapride on antroduodenal motor function in healthy subjects and diabetics with autonomic neuropathy. Aliment Pharmacol Therap 1991, 5:599–608.

    Article  CAS  Google Scholar 

  54. Camilleri M, Malagelada J-R, Abell TL, et al.: Effect of six weeks of treatment with cisapride in gastroparesis and intestinal pseudo-obstruction. Gastroenterology 1989, 96:705–712.

    Google Scholar 

  55. McHugh S, Lico S, Diamant NE: Cisapride versus metoclopramide: an acute study in diabetic gastroparesis. Dig Dis Sci 1992, 37:997–1001.

    Article  PubMed  CAS  Google Scholar 

  56. Richards RD, Valenzuela JA, Davenport KS, et al.: Objective and subjective results of a randomized, doubleblind, placebo-controlled trial using cisapride to treat gastroparesis. Dig Dis Sci 1993, 38:811–816.

    Article  PubMed  CAS  Google Scholar 

  57. Di-Lorenzo C, Reddy SN, Villanueva-Meyer J, et al.: Cisapride in children with chronic intestinal pseudoobstruction. An acute, double-blind crossover, placebocontrolled trial. Gastroenterology 1991, 101:1564–1570.

    PubMed  CAS  Google Scholar 

  58. Camilleri M, Balm RK, Zinsmeister AR. Determinants of response to a prokinetic agent in neuropathic chronic intestinal motility disorder. Gastroenterology 1994, 106:916–923.

    PubMed  CAS  Google Scholar 

  59. Bedford TA, Rowbotham DJ. Cisapride. Drug interactions of clinical significance. Drug Saf 1996, 15:167–175.

    Article  PubMed  CAS  Google Scholar 

  60. Soudah HC, Hasler WL, Owyang C: Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma. New Engl J Med 1991, 325:1461–1467.

    Article  PubMed  CAS  Google Scholar 

  61. O’Donnell LJD, Watson AJM, Cameron D, et al.: Effect of octreotide on mouth-to-cecum transit time in healthy subjects in the irritable bowel syndrome. Aliment Pharmacol & Therap 1990, 4:177–182.

    Article  CAS  Google Scholar 

  62. Maes BD, Ghoos YF, Geypens BJ, et al.: Influence of octreotide on the gastric emptying of solids and liquids in normal healthy subjects. Aliment Pharmacol Ther 1995, 9:11–18.

    Article  PubMed  CAS  Google Scholar 

  63. Bassotti G, Germani U, Calcara C, et al.: Effects of octreotide on manometric variables in patients with neuropathic abnormalities of the small bowel. Dig Dis Sci 1997, 42:1643–1649.

    Article  Google Scholar 

  64. Haruma K, Wiste JA, Camilleri M: Effect of octreotide on gastrointestinal pressure profiles in health and in functional and organic gastrointestinal disorders. Gut 1994, 35:10649.

    Google Scholar 

  65. Nelson-Piercy C, Hammond PH, Gwilliam ME, et al.: Effect of a new oral somatostatin analog [SDZ CO 611] on gastric emptying, mouth-to-cecum transit time and pancreatic and gut hormone release in normal male subjects. J Clin Endocrinol Metab 1994, 78:329–336.

    Article  PubMed  CAS  Google Scholar 

  66. Von-der-Ohe MR, Camilleri M, Thomforde GM, Klee GG: Differential regional effects of octreotide on human gastrointestinal motor function. Gut 1995, 36:743–748.

    PubMed  CAS  Google Scholar 

  67. Hasler WL, Soudah HC, Owyang C: A somatostatin analogue inhibits afferent pathways mediating perception of rectal distension. Gastroenterology 1993, 104:1390–1397.

    PubMed  CAS  Google Scholar 

  68. Bradette M, Delvaux M, Staumont G, et al.: Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994, 39:1171–1178.

    Article  PubMed  CAS  Google Scholar 

  69. Hussaini SH, Pereiera SP, Veysey MJ, et al.: Roles of gall bladder emptying and intestinal transit in the pathogenesis of octreotide induced gall bladder stones. Gut 1996, 38:775–783.

    PubMed  CAS  Google Scholar 

  70. Redfern JS, Fortuner WJ II: Octreotide-associated biliary tract dysfunction and gallstone formation: pathophysiology and management. Am J Gastroenterol 1995, 90:1042–1052.

    PubMed  CAS  Google Scholar 

  71. Stolk MF, van Erpecum KJ, Koppeschaar HP, et al.: Effect of octreotide on fasting gall bladder emptying, antroduodenal motility, and motilin release in acromegaly. Gut 1995, 36:755–760.

    PubMed  CAS  Google Scholar 

  72. Tack J, Janssens J, Vantrappen G, et al.: Effect of erythromycin on gastric motility in controls and in diabetic gastroparesis. Gastroenterology 1992, 103:72–79.

    PubMed  CAS  Google Scholar 

  73. Fraser R, Shearer T, Fuller J, et al.: Intravenous erythromycin overcomes small intestinal feedback on antral, pyloric and duodenal motility. Gastroenterology 1992, 103:116–119.

    Google Scholar 

  74. Janssens J, Peeters TL, Vantrappen G, et al.: Improvement of gastric emptying in diabetic gastroparesis by erythromycin. N Engl J Med 1990, 322:1028–1031.

    Article  PubMed  CAS  Google Scholar 

  75. Weber FH, Richards RD, McCallum RW: Erythromycin: a motilin agonist and gastrointestinal prokinetic agent. Am J Gastroenterol 1993, 88:485–490.

    PubMed  CAS  Google Scholar 

  76. Keshavarzian A, Isaac RM: Erythromycin accelerates gastric emptying of indigestible solids and transpyloric migration of the tip of an enteral feeding tube in fasting and fed states. Am J Gastroenterol 1993, 88:193–197.

    PubMed  CAS  Google Scholar 

  77. Mantides A, Xynos E, Chrysos E, et al.: The effect of erythromycin in gastric emptying of solids and hypertonic liquids in healthy subjects. Am J Gastroenterol 1993, 88:198–202.

    PubMed  CAS  Google Scholar 

  78. Paz HL, Weinar M, Sherman MS: Motility agents for the placement of weighted and unweighted feeding tubes in critically ill patients. Intensive Care Med 1996, 22:301–304.

    PubMed  CAS  Google Scholar 

  79. Tack J: Georges Brohee Prize 1994. Motilin and the enteric nervous system in the control of interdigestive and postprandial gastric motility. Acta Gastroenterol Belg 1995, 58:21–30. A detailed review of the history of the development of erythromycin as a prokinetic - by a member of the group that has spearheaded this area.

    PubMed  CAS  Google Scholar 

  80. Stern MA, Wolf DC: Erythromycin as a prokinetic agent. A prospective, randomized, controlled study of efficacy in nasoenteric tube placement. Am J Gastroenterol 1994, 89:2011–2013.

    PubMed  CAS  Google Scholar 

  81. Bjornsson ES, Abrahamsson H: Comparison between physiologic and erythromycin-induced interdigestive motility. Scand J Gastroenterol 1995, 30:139–145.

    PubMed  CAS  Google Scholar 

  82. Sarna SK, Soergel KH, Koch TR, et al.: Gastrointestinal motor effects of erythromycin in humans. Gastroenterology 1991, 101:1488–1496.

    PubMed  CAS  Google Scholar 

  83. Fiorucci S, Distrutti E, Bassotti G, et al.: Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastro 1994, 29:807–813.

    CAS  Google Scholar 

  84. Cucchiara S, Minella R, Scoppa A, et al.: Antroduodenal motor effects of intravenous erythromycin in children with abnormalities of gastrointestinal motility. J Pediatr Gastroenterol Nutr 1997, 24:411–418.

    Article  PubMed  CAS  Google Scholar 

  85. Ng PC, Fok TF, Lee CH, et al.: Erythromycin treatment for gastrointestinal dysmotility in preterm infants. J Pediatr Child Health 1997, 33:148–150.

    CAS  Google Scholar 

  86. Samsom M, Jebbink RJ, Akkermans LM, et al.: Effects of oral erythromycin on fasting and postprandial antroduodenal motility in patients with type I diabetes, measured with an ambulatory manometric technique. Diabetes Care 1997, 20:129–134.

    Article  PubMed  CAS  Google Scholar 

  87. Minimi T, Nishibayashi H, Shinomura Y, Matsuzawa Y: Effects of erythromycin in chronic idiopathic intestinal pseudo-obstruction. J Gastroenterol 1996, 31:855–859.

    Article  Google Scholar 

  88. Fiorucci S, Distrutti E, Bassotti G, et al.: Effect of erythromycin administration on upper gastrointestinal motility in scleroderma patients. Scand J Gastroenterol 1994, 29:807–813.

    PubMed  CAS  Google Scholar 

  89. Fiorucci S, Distrutti E, Gerli R, Morelli A: Effect of erythromycin on gastric and gallbladder emptying and gastrointestinal symptoms in scleroderma patients is maintained medium term. Am J Gastroenterol 1994, 89:550–555.

    PubMed  CAS  Google Scholar 

  90. Minocha A, Katragadda R, Rahal PS, Ries A: Erythromycin shortens orocecal transit time in diabetic male subjects: a double-blind placebo-controlled study. Aliment Pharmacol Ther 1995, 9:529–533.

    Article  PubMed  CAS  Google Scholar 

  91. Altomare DF, Rubini D, Pilot MA, et al.: Oral erythromycin improves gastrointestinal motility and transit after subtotal but not total gastrectomy for cancer. Eur J Surg 1997, 84:1017–1021.

    CAS  Google Scholar 

  92. Mathis C, Malbert CH: Gastric but not duodenal motor effects of oral erythromycin are dose related. Neurogastroenterol-Motil 1995, 7:47–54.

    PubMed  CAS  Google Scholar 

  93. Camilleri M: The current role of erythromycin in the clinical management of gastric emptying disorders. Am J Gastroenterol 1993, 88:169–171.

    PubMed  CAS  Google Scholar 

  94. DiBiase J, Quigley EMM: Long Term Therapy with Intravenous Erythromycin. J. Clin. Gastro (In Press).

  95. Murr MM, Sarr MG, Camilleri M: The surgeon’s role in the treatment of chronic intestinal pseudoobstruction. Am J Gastroenterol. 1995, 90[12]:2147–2151. Summarizes the experience of one major referral center in the role of surgery in patients with severe dysmotility syndromes.

    Google Scholar 

  96. Vanderhoof JA, Langnas AN, Pinch LW, et al.: Short bowel syndrome and intestinal transplantation. Ped Gastro and Nutr 1992, 14:359–370.

    Article  CAS  Google Scholar 

  97. MacGilchrist AJ, Quigley EMM: Transplantation. In: Diseases of the GI Tract and Liver. Sherman D, Finlayson NDC, Carter D, Camilleri M. eds. London: Churchill Livingstone; 1997.

    Google Scholar 

  98. Quigley EMM: Small Intestinal Transplantation. Reflections on an evolving approach to intestinal failure. Gastroenterology 1996, 110:2009–2012.

    Article  PubMed  CAS  Google Scholar 

  99. Mathias JR, Baskin GS, Reeves-Darby VG, et al.: Chronic intestinal pseudo-obstruction in a patient with heartlung transplant: therapeutic effect of leuprolide acetate. Dig Dis Sci 1992, 37:1761–1768.

    Article  PubMed  CAS  Google Scholar 

  100. Rutgeerts P, Vantrappen G, Hiele M, et al.: Effects on bowel motility of misoprostol administered before and after meals. Aliment Pharmacol Therap 1991, 5:533–542.

    Article  CAS  Google Scholar 

  101. Soffer EE, Launspach J: Effect of misoprostol on postprandial intestinal motility and orocecal transit time in humans. Dig Dis Sci 1993, 38:851–855.

    Article  PubMed  CAS  Google Scholar 

  102. Kreek M-J, Schaefer RA, Hahn EF, Fishman J: Naloxone, a specific opioid antagonist, reverses chronic idiopathic constipation. Lancet 1983, 1:261–262.

    Article  PubMed  CAS  Google Scholar 

  103. Fraitag B, Homerin M, Hecketsweiler P: Double-blind dose-response multicenter comparison of fedotozine and placebo in treatment of non-ulcer dyspepsia. Dig Dis Sci 1994, 39:1072–1077.

    Article  PubMed  CAS  Google Scholar 

  104. Read NW, Abitbol JL, Bardhan KD, et al.: Efficacy and safety of the peripheral kappa against fedotozine versus placebo in the treatment of functional dyspepsia. Gut 1997, 41:664–668.

    Article  PubMed  CAS  Google Scholar 

  105. Verhangen MA, Samsom, M, Maes B, et al.: Effects of a new motilide, ABT-229 on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997, 11:1077–1086.

    Article  Google Scholar 

  106. Okano H, Inui A, Ueno N, et al.: EM523L, a nonpeptide motilin agonist, stimulates gastric emptying and pancreatic polypeptide secretion. Peptides 1996, 17:895–900.

    Article  PubMed  CAS  Google Scholar 

  107. Lartey PA, Nellans HN, Faghih R, et al.: Synthesis of 4′-deoxy motilides: identification of a potent and orally active prokinetic drug candidate. J Med Chem 1995, 38:1793–1798.

    Article  PubMed  CAS  Google Scholar 

  108. Kawamura O, Sekiguchi T, Itoh Z, Omura S: Effect of erythromycin derivative EM523L on human interdigestive gastrointestinal tract. Dig Dis Sci 1993, 38:1026–1031.

    Article  PubMed  CAS  Google Scholar 

  109. Sifrim D, Janssens J, Vantrappen G: Effect of midecamycin acetate on gastrointestinal motility in humans. Int J Clin Pharmacol Res 1992, 12:71–79.

    PubMed  CAS  Google Scholar 

  110. Tougas G, Huizinga JD:. Gastric pacing as a treatment for intractable gastroparesis: Shocking news? Gastroenterology 1998, 114:598–601.

    Article  PubMed  CAS  Google Scholar 

  111. Brand RM, Lof J, Quigley EM: Transdermal delivery of erythromycin lactobionate3īmplications for the therapy of gastroparesis. Aliment Pharmacol Ther 1997, 11:589–592.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, University of Nebraska Medical Center, 68198-2000, Omaha, NB

    Eamonn M. M. Quigley MD, FRCP

Authors
  1. Eamonn M. M. Quigley MD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quigley, E.M.M. Chronic intestinal pseudo-obstruction. Curr Treat Options Gastro 2, 239–250 (1999). https://doi.org/10.1007/s11938-999-0063-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-999-0063-9

Keywords

Search

Navigation